Two Egyptian-Manufactured Medicines are Soon Entering Europe and Canada
Cairo, 27 August 2020 — EVA Pharma announces a license agreement with a global pharmaceutical company to co-manufacturer large quantities of two medicines, one is an anticoagulant that is used with COVID-19 patients, and the other treats benign prostatic hyperplasia (BPH). The drugs will soon be available in European countries and in Canada.
The news comes after the conclusion of all registration procedures with the relevant authorities at the European Union and Canada, with ensuring the drugs are produced, in EVA Pharma’s manufacturing facilities in Egypt, under the best global pharmaceutical standards of quality.
The managing director of Elbe life sciences, which is located in Hamburg, Germany, and owned by EVA Pharma, Dr. Nicolas Boge, spoke on the company’s continuous abidance by the top global quality standards in pharmaceutical manufacturing for locally distributed products as well as exported products. He pointed to the company’s plan to expand its production of medicines to European countries and other places around the world in addition to making available new medicines first to be introduced to the Egyptian market.
Boge revealed: “the first drug, which will soon be available in the Canadian market, is apixaban, an anticoagulant that is used to prevent blood clotting. The medicine is used with some cardiovascular diseases and recently has been used to prevent coagulation with some COVID-19 patients. While the second drug is solifenacin, treatment of benign prostatic hyperplasia (BPH), and soon will be available in European countries.
The anticoagulant Apixatrack® and BPH treatment Solitract®, like many other EVA Pharma products, already available in the Egyptian market and have gained the trust of many physicians and patients alike.